Description
VildagliptinisaninhibitorofdipeptidylpeptidaseIV(DPP4)thatincreaseslevelsofglucagon-likepeptide1(GLP-1).Vildagliptin’sinhibitionofDPP4resultsinanti-diabeticandanti-hyperglycemicbenefits,includingincreasesinseruminsulinandβ-cellmass,decreasesinserumglucagon,restorationofinsulin/IGF1signaling,andimprovedendoplasmicreticularstressinanimalmodels.Additionally,thiscompounddisplaysneuroprotectiveandcognitionenhancingactivities,attenuatingamyloid-β(Aβ)pathology,tauphosphorylation,andreleaseofinflammatoryMarkersaswellasimprovingmemoryretentioninanimalmodels;thisindicatespotentialbenefitasatreatmentforAlzheimer’sdiseasewithfurtherinvestigation.
References
KosarajuJ,MurthyV,KhatwalRB,etal.Vildagliptin:ananti-diabetesagentamelioratescognitivedeficitsandpathologyobservedinstreptozotocin-inducedAlzheimer"sdisease.JPharmPharmacol.2013Dec;65(12):1773-84.PMID:24117480.
ShimizuS,HosookaT,MatsudaT,etal.DPP4inhibitorvildagliptinpreservesβ-cellmassthroughameliorationofendoplasmicreticulumstressinC/EBPBtransgenicmice.JMolEndocrinol.2012Aug30;49(2):125-35.PMID:22822047.
ThornberryNA,GallwitzB.Mechanismofactionofinhibitorsofdipeptidyl-peptidase-4(DPP-4).BestPractResClinEndocrinolMetab.2009Aug;23(4):479-86.PMID:19748065.
BalasB,BaigMR,WatsonC,etal.ThedipeptidylpeptidaseIVinhibitorvildagliptinsuppressesendogenousglucoseproductionandenhancesisletfunctionaftersingle-doseadmiNISTrationintype2diabeticpatients.JClinEndocrinolMetab.2007Apr;92(4):1249-55.PMID:17244786.
